As Immigration and Customs Enforcement (ICE) presence and operations in the area increase, some schools that closed as a ...

The researcher is a pioneer in techniques for manipulating mice brains to change how they recall past events ...

Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA ...

Magnetically modifying your Altoids tin for enhanced EDC functionality. Trump threatens Raytheon's business with the US ...

The Town Council will consider modifying construction waivers to allow barge transport without bridge openings.

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Explore why tau still lacks treatments despite its critical role in Alzheimer's disease and other tauopathies.

About XTL Biopharmaceuticals Ltd. XTL is an IP Portfolio company that holds 100% of The Social Proxy Ltd. and IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) that the company ...

Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for ...

ODI% (Functional Disability): Mean improvement of −15.3 percentage points at 180 days (p = 0.0003; large effect size). Approximately 79% of patients achieved clinically meaningful functional ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate ...